A Double-blind, Placebo-controlled, Randomised, Single dose, Dose-ascending study to Evaluate the Safety, Tolerability and Pharmacokinetics of TRC160334 administered intravenously to male and female healthy subjects (Part A) and elderly subjects with renal impairment (Part B)
Latest Information Update: 25 Nov 2019
At a glance
- Drugs TRC 160334 (Primary)
- Indications Acute kidney injury; Inflammatory bowel diseases
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Torrent Pharmaceuticals
Most Recent Events
- 25 Nov 2019 New trial record
- 22 Nov 2019 Results presented in a document of Minutes of IND Committee meeting held on 15.03.2019 at ICMR.